Risk tracking test for Crohn’s disease in teens
Part of Digestive system clinical trials.
This study checks whether a personalized tool can estimate someone’s risk for Crohn’s disease before symptoms start. It may help families learn early risk and decide on next steps sooner.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You can read, understand, and sign a consent form
- You can attend all study visits and follow study instructions
- You can understand and complete the study questionnaires
- You are at least 15 years old
- A parent, sibling, or child has inflammatory bowel disease (Crohn’s, ulcerative colitis, or IBD “unclassified”)
- You do not already have a diagnosed inflammatory bowel disease
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study follows people who have a parent, sibling, or child with Crohn's disease or ulcerative colitis to help understand why some family members develop the condition. If you are 14 or older and do not already have IBD, you may be able to join.
This study tests if a planning tool helps teenagers with Crohn's disease or ulcerative colitis manage their condition. It's for patients aged 13 to 19 who have had their diagnosis for at least 3 months and are seen at UNC.
This study looks for “biomarkers” (lab markers, like substances in blood or tissue) that may predict how Crohn’s disease or ulcerative colitis will go and how patients may respond. It may help doctors choose better monitoring or treatments in the future.
This study follows children newly diagnosed with Crohn’s disease to see how results from scans and endoscopy (camera scope) relate to outcomes over the first year. It may help doctors choose better early treatment plans and monitor children more effectively.
This study checks whether adding an extra, cross-body “transmural” evaluation (looking at inflammation throughout the bowel) improves care for adults with Crohn’s who are starting or receiving biologic (biotherapy) treatment. It uses close follow-up with stool calprotectin (a marker of gut inflammation) to see if this approach helps control inflammation.
This study looks at proteins from your body and gut bacteria to understand Crohn's disease better. You may join if you are about to have your first colonoscopy for suspected Crohn's and have not had any treatment yet.
Hear when a new Crohn's Ileocolitis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.